Zevra Therapeutics Overview
Valuation check: KMPH's ROE is 26.77%, above the Healthcare sector average of 11.15%.
Get informed when a big investor buys or sells
+ Follow26.77%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Zevra Therapeutics (KMPH) currently reports a ROE of 26.77%. That is above the Healthcare sector average of 11.15%. Use the charts on this page to explore Zevra Therapeutics's ROE history and peer comparisons.
Zevra Therapeutics's ROE of 26.77% is higher than the Healthcare sector average of 11.15%. That is roughly 140.0% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Zevra Therapeutics's current 26.77% should be judged against Healthcare norms (sector average: 11.15%) and against KMPH's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 26.77%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for Zevra Therapeutics, and consider following KMPH for alerts when major investors trade the stock.
Zevra Therapeutics is classified in the Healthcare sector. On ROE, it currently shows 26.77% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing KMPH with unrelated industries.
